GRITSTONE ONCOLOGY INC's ticker is GRTS and the CUSIP is 39868T105. A total of 73 filers reported holding GRITSTONE ONCOLOGY INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $30,960 | -11.8% | 18,000 | 0.0% | 0.00% | – |
| Q2 2023 | $35,100 | -79.8% | 18,000 | -57.3% | 0.00% | – |
| Q1 2022 | $174,000 | -67.8% | 42,200 | +0.2% | 0.00% | – |
| Q4 2021 | $541,000 | +52.0% | 42,100 | +27.6% | 0.00% | – |
| Q3 2021 | $356,000 | +18.3% | 33,000 | 0.0% | 0.00% | – |
| Q2 2021 | $301,000 | +30.9% | 33,000 | +35.2% | 0.00% | – |
| Q1 2021 | $230,000 | +42.9% | 24,400 | -40.2% | 0.00% | – |
| Q4 2020 | $161,000 | +49.1% | 40,800 | 0.0% | 0.00% | – |
| Q3 2020 | $108,000 | -63.6% | 40,800 | -8.9% | 0.00% | – |
| Q2 2020 | $297,000 | +92.9% | 44,800 | +69.7% | 0.00% | – |
| Q1 2020 | $154,000 | -7.8% | 26,400 | +41.9% | 0.00% | – |
| Q4 2019 | $167,000 | +3.7% | 18,600 | 0.0% | 0.00% | – |
| Q3 2019 | $161,000 | +10.3% | 18,600 | +42.0% | 0.00% | – |
| Q2 2019 | $146,000 | -48.8% | 13,100 | -34.5% | 0.00% | – |
| Q3 2018 | $285,000 | – | 20,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 3,102,929 | $18,059,047,000 | 4.95% |
| Svennilson Peter | 3,102,934 | $18,059,000 | 2.29% |
| Casdin Capital, LLC | 2,270,000 | $13,211,000 | 1.40% |
| FRAZIER MANAGEMENT LLC | 2,061,758 | $11,999,000 | 1.36% |
| Redmile Group, LLC | 3,068,194 | $17,857,000 | 0.50% |
| Alphabet Inc. | 929,022 | $5,407,000 | 0.36% |
| Bleichroeder LP | 169,039 | $984,000 | 0.26% |
| Leap Investments LP | 14,400 | $84,000 | 0.12% |
| DAFNA Capital Management LLC | 50,000 | $291,000 | 0.12% |
| Blackstone Inc. | 2,567,445 | $14,943,000 | 0.11% |